Bruno Guedes Baldi: University of Sao Paulo Medical School, Brazil
Niranjan Jeganathan: Loma Linda University Health System School of Medicine, US
Jin Woo Song: University of Ulsan College of Medicine, South Korea
Submission Status: Open | Submission Deadline: 8 April 2024
BMC Pulmonary Medicine is calling for submissions to our Collection on connective tissue disease-associated interstitial lung disease. Interstitial Lung Disease (ILD) is a common manifestation of several systemic autoimmune connective tissue diseases (CTDs). While ILD can manifest with all CTDs, it most commonly affects individuals with rheumatoid arthritis (RA, 10-30%), systemic sclerosis (SSc, 40-80%), and idiopathic inflammatory myopathy (IIM, 40%). In some patients, ILD could also be the initial or only manifestation of an underlying CTD and the research classification “interstitial pneumonia with autoimmune features (IPAF)” was recently proposed to identify these patients. ILD poses a significant burden, contributing to morbidity and mortality among CTD patients. Given the complexity in the diagnosis and treatment of CTD-related ILD, a multidisciplinary approach to management is crucial.